Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: A randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy
Open Access
- 15 April 2013
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 22 (3) , 263-267
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version)Breast Cancer, 2007
- Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancerCancer, 2006
- Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative TherapyClinical Cancer Research, 2005
- Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized TrialJournal of Clinical Oncology, 2005
- Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapyEuropean Journal of Cancer, 2001
- Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18Journal of the National Cancer Institute Monographs, 2001
- Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter studyAnnals of Oncology, 2001
- Influence of Endocrine-Related Factors on Response to Perioperative Chemotherapy for Patients With Node-Negative Breast CancerJournal of Clinical Oncology, 2001
- Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-upEuropean Journal of Cancer, 1992
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989